Our vision is to help people live healthier, happier lives, by developing cutting edge medical solutions that will increase procedural efficacy while enhancing patient safety. We believe patient safety is the utmost priority, and all of our efforts are dedicated to bringing products to market that lower the risks associated with medical interventions.

Roy Doumani


Roy Doumani is a professor at the David Geffen School of Medicine at UCLA, teaching “The Business of Science” to PhD candidates and post-doctoral fellows and is the Executive Director of the UCLA Business of Science Center. He was active in the formation of the California NanoSystems Institute and currently serves as Co-Chairman of the Zhejiang California NanoSystems Institute in China.

With a background in international finance and banking, Roy holds an equity position in and serves as Vice Chairman of the first joint venture bank in the PRC, Xiamen International Bank and has been involved with numerous financial institutions: Founder and Director of First Los Angeles Bank; Chairman of First Interstate Bank of Hawaii; Director of HonFed Bank; and Chairman of World Trade Bank in Los Angeles. Roy has served as a board member and advisor to companies in the United States, Asia, Europe and the Middle East.

Roy is a member of RAND’s Center for Asia Pacific Policy’s advisory board and Chairman of the Pacific Pension Institute’s advisory board. He is also a trustee of the Norton Simon Museum. He has established endowed chairs at UCLA in the Departments of Medical and Molecular Pharmacology and Urological Oncology.

Roy Doumani graduated from the University of California at Los Angeles (UCLA) with a degree in Business and Finance and received his JD from the University of Southern California.

Kalyanam Shivkumar, M.D., Ph.D., FHRS, FACC


Dr. Shivkumar serves as a Professor of Medicine, Radiology, and Bioengineering at the University of California, Los Angeles. Dr. Shivkumar received his medical degree from the University of Madras, India in 1991. He completed a residency in Internal Medicine and was Chief Medical Resident at Henry Ford Hospital (Michigan). He completed his cardiology fellowship training at the University of California, Los Angeles and received his PhD from UCLA in 2000. Upon completion of his training, he joined the faculty at University of Iowa as the Associate Director of Cardiac Electrophysiology. In 2002, he was recruited back to UCLA as Director of the newly created UCLA Cardiac Arrhythmia Center at the David Geffen School of Medicine at UCLA. His field of specialization is interventional cardiac electrophysiology and he heads a group at UCLA that is involved in providing state of the art care and is also developing innovative techniques for the non-pharmacological management of cardiac arrhythmias. Dr. Shivkumar also serves as the academic director of Cardiac Electrophysiology at West Los Angeles VA Medical Center.

Dr. Shivkumar is certified by the American Board of Internal Medicine in the subspecialties of Cardiovascular Disease and Clinical Cardiac Electrophysiology. He holds memberships in several professional organizations, including the American Heart Association, American College of Cardiology and the Heart Rhythm Society. He has been elected as a Fellow of the Heart Rhythm Society and the American College of Cardiology. Dr. Shivkumar’s research works deals with mechanisms of cardiac arrhythmias in humans including the role of the autonomic nervous system in arrhythmias. His group is actively involved in mechanistic studies, complex catheter ablation, development of new IP and medical technology for cardiovascular therapeutics. He has founded several medical technology companies and is actively involved in promoting biomedical innovations at UCLA. He serves on the editorial board of the journals Heart Rhythm, PACE and is a peer reviewer for several basic science and clinical journals in cardiology. He also serves as a peer reviewer for the NIH in evaluating cardiac arrhythmia research.

Raghuveer Mendu

Co-Founder of Ventureast (APIDC), one of the early VC funds in India. Ventureast is focused on growth and early stage companies. Ventureast has launched 4 funds since inception that includes several firsts in the field in India. He is focused on technology companies in areas that leverage India’s skills or serve India’s needs.

As an entrepreneur, he has founded and built four companies over the past 20 years (and acquired 7 and sold 4 in this time) in the banking, technology products and services industries, growing one of them from $5MM to $135MM in 15 months. His first company was one of India’s earliest software product companies.

As an EVP and founding team member ran a technology subsidiary for Union Bank in Los Angeles. Prior to that, he was responsible for the Financial Industry Division for Nixdorf Computer in the US. Also managed the product development group at Nixdorf.

Co-founded The Heart of a Child Foundation, a non-profit that supports children born with heart defects and research in the area of Congenital Heart Defects.

Raghu has an MBA from the University of Michigan, and an undergraduate engineering degree from the Indian Institute of Technology in Madras, India.

N.C. Murthy


N.C. has been an entrepreneur in the technology sector for more than 25 years. N.C.’s companies have been recognized in Inc. and Florida Trend magazines as being among the fastest growing companies in the US and Florida, respectively. N.C. founded an information technology staffing and consulting services company, Online Resources, in 1991 and grew the operations to more than 220 consultants and $20 million in revenue within four years. He sold the company to a large publicly traded company (CoreStaff), remaining as a senior executive in charge of the International development and recruiting activities.

Following his success at Online Resources, N.C., in partnership with Raghu Mendu, purchased Metamor Enterprise Solutions. Metamor, an authorized reseller of SAP, was the only company in the US to develop a pre-configured client-based methodology (QuickwearTM) to facilitate fast, efficient implementations of SAP for small to mid-sized companies in the apparel and footwear industry. Metamor was later acquired by Headstrong, a global business consulting and IT technology services firm. In 2005,

N.C. furthered his entrepreneurial career with the purchase of the EZ-CAP medical claims and benefits administration product line from a struggling software company. The company rapidly undertook a major redesign of the product suite, and, within six months, the product line and client base had been revitalized. In 2014, following an almost ten-year period in which the company’s sales doubled, N.C. sold the company to a Jacksonville based company backed by investments from Great Point Partners and Allscripts. Apart from his experience in the technology and staffing sectors, N.C. served as a director in a SPAC (Special Purpose Acquisition Company) formed to raise $80,000,000 on Wall Street.

NC earned a Bachelor’s degree in Mechanical Engineering at Osmania University in Hyderabad, India and earned a Masters in Industrial Engineering from the National Institute of Industrial Engineering in Mumbai, India.

Kalpesh Patel

Kalpesh Patel is a Pharmacist by training. He is the CEO of Michael Franklin (Chemists) Limited, a United Kingdom based retail Pharmacy chain. He has extensive experience in setting up and running Pharmacy chains, including Glenhazel Limited, which was set up in 2004 using seed money and eventual multi million pound sale to Safedale Limited in 2015. He is also a Director of Rickon Limited, a property investment and redevelopment company, which buys, renovates, and rents domestic properties in the UK. Kalpesh is also involved in Pharmacy politics, having been chair of Buckinghamshire Pharmaceutical Committee for thirteen years and a member for over twenty years. He has also served on the Pharmaceutical Services negotiating committee, the organisation which negotiates the pharmacy contract and remuneration with the National Health Service of England and Wales.

Our vision is to help people live healthier, happier lives, by developing cutting edge medical solutions that will increase procedural efficacy while enhancing patient safety. We believe patient safety is the utmost priority, and all of our efforts are dedicated to bringing products to market that lower the risks associated with medical interventions.